Precigen, Inc. (PGEN)
PGEN Stock Price Chart
Explore Precigen, Inc. interactive price chart. Choose custom timeframes to analyze PGEN price movements and trends.
PGEN Company Profile
Discover essential business fundamentals and corporate details for Precigen, Inc. (PGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Aug 2013
Employees
143.00
Website
https://www.precigen.comCEO
Helen Sabzevari MPH,
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
PGEN Financial Timeline
Browse a chronological timeline of Precigen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.08, while revenue estimate is $900.00K.
Earnings released on 12 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%, while revenue for the quarter reached $856.00K , missing expectations by -8.29%.
Earnings released on 14 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $1.34M , beating expectations by +168.20%.
Earnings released on 19 Mar 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $1.19M , beating expectations by +62.27%.
Earnings released on 14 Nov 2024
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $953.00K , missing expectations by -26.69%.
Earnings released on 14 Aug 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $717.00K , missing expectations by -43.98%.
Earnings released on 14 May 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $1.07M , missing expectations by -28.04%.
Earnings released on 13 Feb 2024
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $1.23M .
Earnings released on 9 Nov 2023
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $1.38M , missing expectations by -18.88%.
Earnings released on 9 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $1.77M , missing expectations by -18.94%.
Earnings released on 10 May 2023
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%, while revenue for the quarter reached $1.85M , missing expectations by -16.62%.
Earnings released on 6 Mar 2023
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $1.76M , missing expectations by -71.61%.
Earnings released on 9 Nov 2022
EPS came in at -$0.04 falling short of the estimated $0.10 by -140.00%, while revenue for the quarter reached $16.72M , beating expectations by +514.78%.
Earnings released on 8 Aug 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $2.91M , missing expectations by -87.08%.
Earnings released on 9 May 2022
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $32.02M , beating expectations by +13.05%.
Earnings released on 1 Mar 2022
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%, while revenue for the quarter reached $24.22M , missing expectations by -0.34%.
Earnings released on 8 Nov 2021
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $21.56M , missing expectations by -9.64%.
Earnings released on 9 Aug 2021
EPS came in at -$0.01 , while revenue for the quarter reached $33.58M .
Earnings released on 9 Aug 2021
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $33.58M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $24.51M , beating expectations by +28.06%.
Earnings released on 1 Mar 2021
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $19.33M , missing expectations by -12.99%.
Earnings released on 9 Nov 2020
EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%, while revenue for the quarter reached $23.58M , beating expectations by +40.00%.
PGEN Stock Performance
Access detailed PGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.